"Ozempic face" is an informal, non-medical nickname for visible facial changes like reduced fullness, a hollow or deflated look, and skin that appears looser, drier, or more lined that some people notice during or after substantial weight loss, including weight loss while using GLP-1-based medications. Rapid facial fat loss is a major part of the explanation. Researchers are also examining whether GLP-1 therapy may be associated with changes in the quality of the skin itself, including firmness, elasticity, hydration, and texture. The science is still evolving, but there are practical ways to support how your skin looks throughout the journey.
What people mean by "Ozempic face"
The phrase became widely used as medications such as semaglutide and the dual GIP/GLP-1 medication tirzepatide became more common in diabetes care and weight management under brand names including Ozempic®, Wegovy®, Zepbound®, and Mounjaro®. Approved indications vary by product. "Ozempic face" is media shorthand, not a medical diagnosis, and facial aging or facial volume loss is not identified as an adverse reaction in current FDA-approved Ozempic prescribing information.8 The phrase is generally used to describe a cluster of visible changes that may accompany substantial or rapid weight loss, including:
- A flatter or more "deflated" look in the cheeks
- More prominent bone structure and hollowing under the eyes
- Skin that appears looser along the jawline
- Fine lines and folds that look more noticeable
- An overall tired or gaunt appearance
More than one factor may be involved
The best-established explanation is straightforward: when facial fat decreases quickly, the skin can look deflated. The face contains fat compartments that contribute to a smooth, full appearance, and when they shrink, the overlying skin may look looser or more lined. A 2024 dermatology review also proposed that GLP-1-related facial changes may be multifactorial, potentially involving adipose tissue, muscle, hormonal signaling, and the skin's supportive structure.1 Direct medication effects on human facial skin have not yet been established, so it is important to distinguish emerging biological theories from proven causation. Aforé's clinical study addressed a separate question: whether DermaReverse could support visible skin quality in people already using GLP-1 therapy when compared with placebo.
Why can facial appearance change during a GLP-1 journey?
Several factors may contribute, and they can overlap:
Rapid fat loss
Facial fat gives the skin underlying volume. When it decreases quickly, the overlying skin can look deflated or looser because there is less fullness beneath it.
Skin may take time to adjust
Collagen and elastin help give skin its firm, resilient appearance. Their natural levels decline with age, and after substantial or rapid weight loss, the skin may not visibly adjust to smaller facial contours at the same pace — making lines or laxity look more noticeable.
Changes in muscle and underlying support
Weight loss can include both fat and lean mass. Because muscle contributes to the underlying support of the face and body, clinicians often discuss adequate protein intake and resistance training as part of a medically supervised weight-management plan.
Emerging research: the quality of the skin itself
Researchers are examining whether GLP-1-based medications may influence skin biology in addition to producing weight loss. A 2024 review in Aesthetic Surgery Journal described GLP-1-related facial changes as potentially multifactorial, involving loss of dermal and subcutaneous fat, altered activity of adipose-derived stem cells, and downstream effects on the skin's supportive environment.1 GLP-1 is a signaling molecule with activity throughout the body,2 and laboratory and clinical research has shown that GLP-1 receptor agonists can act on keratinocytes and influence inflammatory signaling and wound-healing pathways.3,4 GLP-1 therapy has also been studied in connection with inflammatory skin conditions such as psoriasis, demonstrating biological activity in the skin.5 Broader safety literature continues to examine effects associated with this medication class.6
This evidence provides a scientific basis for continued research, but it does not yet establish that GLP-1 medications directly cause changes in human facial skin independent of weight loss. Nutrition may also play a supporting role: healthy skin renewal depends on adequate intake of nutrients including vitamin A and other micronutrients.7 Because appetite, food intake, or gastrointestinal symptoms can change during GLP-1 treatment, individual nutrition and hydration needs are best discussed with a prescribing clinician or registered dietitian.
When does Ozempic face start?
There is no fixed timeline, and the experience varies from person to person. In general, visible facial changes tend to track with the pace and amount of weight loss: the faster or greater the loss, the more noticeable the change may be. Some people begin to notice differences within the first several months as fat reduction becomes visible in the face, while others notice little or no change. If you are concerned about the pace of weight loss, speak with your prescribing clinician. Do not change your medication, dose, or dosing schedule to address a cosmetic concern without medical guidance.
Does Ozempic face go away? Is it permanent?
There is not enough long-term clinical evidence to predict exactly how often these changes improve after weight stabilizes. What happens over time can depend on several factors:
- Age and skin elasticity — skin with greater natural elasticity may adapt more readily to changing contours.
- How fast and how much weight was lost — larger or faster changes can make volume loss and skin laxity more visible.
- Time at a stable weight — the appearance may continue to evolve after weight loss slows or stabilizes.
- The type of change — lost facial volume, surface dehydration, visible lines, and skin laxity are different concerns and may respond to different approaches.
Some visible changes may soften as weight stabilizes, while others may persist. Supportive skincare can improve the appearance of skin quality, but it cannot replace lost facial volume. For more pronounced concerns, a board-certified dermatologist or plastic surgeon can explain appropriate professional options.
Who is most likely to notice it?
You may be more likely to see noticeable facial changes if you:
- Are losing weight quickly or have lost a substantial amount
- Are older, since skin elasticity naturally decreases with age
- Have had significant sun exposure over time
- Started with more facial fullness that is now decreasing
None of these factors guarantees that a change will occur. Individual experiences vary, and the changes described by the term "Ozempic face" are cosmetic rather than a medical diagnosis.
Ozempic face vs. normal aging: how to tell the difference
The visible changes can overlap, which is why they may be difficult to distinguish. Age-related loss of facial volume and skin quality typically develops gradually over years. Changes noticed during a GLP-1 journey may appear more quickly and often track with the pace of weight loss. In practice, the visible concerns can look similar — less fullness, more noticeable lines, or skin that appears less firm — and many of the appearance-supporting skincare approaches overlap.
What can support the appearance of skin during weight loss?
Options range from everyday habits and consistent skincare to professional procedures. The right approach depends on whether the primary concern is facial volume, skin quality, or both.
Support your body from the inside
- Discuss a healthy rate of weight loss with your clinician — never change your medication, dose, or schedule to address a cosmetic concern without speaking with your prescriber.
- Prioritize adequate protein — protein supports the maintenance of muscle and other tissues. A clinician or registered dietitian can help determine what is appropriate for you.
- Consider resistance training — when medically appropriate, resistance exercise can help support muscle during weight loss.
- Pay attention to hydration — some people may eat or drink less during treatment, and gastrointestinal side effects can contribute to dehydration.8
- Protect against sun exposure — daily broad-spectrum SPF is one of the most consistently recommended steps for maintaining the appearance of skin quality over time.
Support your skin's appearance with a consistent routine
A steady skincare routine cannot change your weight or replace lost facial volume, but appearance-supporting ingredients can help skin look firmer, smoother, and more hydrated. Common options include:
- Peptides — support the look of firmness
- Hyaluronic acid — supports a hydrated, plumper-looking surface
- Retinol and other cosmetic vitamin A derivatives — support the appearance of smoother texture and fewer visible fine lines
- Antioxidants such as vitamin C — support a brighter, more even-looking complexion
Professional options
For more pronounced changes, some people consult a board-certified dermatologist or plastic surgeon about in-office options. These are medical procedures performed by licensed providers, not skincare, and may include injectable fillers to restore volume, energy-based skin-tightening procedures, microneedling, or, for significant loose skin, surgical options. A qualified provider can assess whether any of these approaches is appropriate for you.
Where DermaReverse fits
Aforé developed DermaReverse specifically for people experiencing visible skin-quality changes during or after a GLP-1 journey rather than adapting a general anti-aging product. It is a twice-daily cosmetic serum designed to support the appearance of firmness, smoothness, and hydration.
DermaReverse was evaluated in a peer-reviewed, blinded, placebo-controlled, split-face pilot study. Seven women using GLP-1 therapy applied DermaReverse to one side of the face and placebo to the other twice daily for six weeks while maintaining a stable weight within five pounds. The DermaReverse-treated sides demonstrated statistically significant improvement across all 13 evaluated appearance domains compared with placebo, and no adverse events were reported. The study evaluated DermaReverse's cosmetic effects in GLP-1 users; it was not designed to determine what caused participants' underlying skin concerns. Individual results vary.
Explore DermaReverse · Read the clinical study
Frequently asked questions
Is Ozempic face caused by the medication?
That has not been established. Substantial or rapid weight loss can reduce facial fat and make skin look looser or more lined, whether the weight loss occurs with GLP-1 therapy or through another method. Emerging research is exploring whether GLP-1-based medications may also influence skin biology, but direct effects on human facial skin independent of weight loss have not been proven.
Will Ozempic face go away on its own?
There is limited long-term evidence, and experiences vary. Some visible changes may soften after weight stabilizes, while lost facial volume or more pronounced laxity may persist. Skincare can support the appearance of firmness, smoothness, and hydration, but it cannot replace lost facial volume.
Can skincare fix Ozempic face?
Skincare cannot change your weight or replace lost facial volume. It can, however, support visible skin quality. Appearance-supporting ingredients such as peptides, hyaluronic acid, retinol, and antioxidants can help skin look firmer, smoother, and more hydrated as part of a consistent routine.
How can I reduce visible facial changes while losing weight?
No approach can guarantee prevention. Common supportive steps include discussing an appropriate rate of weight loss with your clinician, consuming adequate protein, incorporating resistance training when medically appropriate, staying hydrated, using daily sun protection, and maintaining a consistent skincare routine. Do not change your medication or dose without speaking with your prescriber.
Is Ozempic face permanent?
Not necessarily, but there is not enough long-term evidence to predict an individual outcome. Some changes may soften as weight stabilizes, while others may remain more noticeable. Age, skin elasticity, the amount and pace of weight loss, and whether the primary concern is volume or skin quality can all influence the appearance over time.
References
- Ridha Z, Fabi SG, Zubair R, Dayan SH. Decoding the Implications of Glucagon-like Peptide-1 Receptor Agonists on Accelerated Facial and Skin Aging. Aesthetic Surgery Journal. 2024;44(11):NP809–NP818. doi:10.1093/asj/sjae132
- Holst JJ. The Physiology of Glucagon-like Peptide 1. Physiological Reviews. 2007;87(4):1409–1439. doi:10.1152/physrev.00034.2006
- Yang J, Wang Z, Zhang X. GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK. Experimental and Molecular Pathology. 2019;107:124–128. doi:10.1016/j.yexmp.2019.01.014
- Nagae K, Uchi H, Morino-Koga S, et al. Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K/Akt pathway in keratinocytes. Diabetes Research and Clinical Practice. 2018;146:155–161. doi:10.1016/j.diabres.2018.10.013
- Xu X, Lin L, Chen P, et al. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. Diabetes Research and Clinical Practice. 2019;150:167–173. doi:10.1016/j.diabres.2019.03.002
- Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. Review of Diabetic Studies. 2014;11(3-4):202–230. doi:10.1900/RDS.2014.11.202
- VanBuren CA, Everts HB. Vitamin A in Skin and Hair: An Update. Nutrients. 2022;14(14):2952. doi:10.3390/nu14142952
- U.S. Food and Drug Administration. Ozempic (semaglutide) Prescribing Information. Revised May 2026. FDA prescribing information
Disclaimer: Aforé and DermaReverse are independent and are not affiliated with, endorsed by, sponsored by, or connected to the makers of Ozempic®, Wegovy®, Zepbound®, Mounjaro®, or any GLP-1 medication. All trademarks are the property of their respective owners and are used here only to describe the topics discussed. "Ozempic face" is an informal, non-medical term and is not a diagnosis. This article discusses cosmetic, appearance-level changes in facial volume and skin quality; it does not establish that any medication causes a disease, medical condition, or specific cosmetic change. References to scientific research are provided for general educational context and include an emerging and evolving area of study. Aforé is a cosmetic skincare company; this content is not medical advice and is not a substitute for consultation with a qualified healthcare provider. Do not change any medication, dose, or treatment plan without speaking with your prescribing clinician. None of Aforé's products are intended to diagnose, treat, cure, or prevent any disease. Individual results vary.